WT1 and acute myeloid leukemia: Based on these results, we suggest that WT1 overexpression by itself could play an important but negative role in predicting DFS and OS of the CN-AML patients; moreover, the WT1 overexpression, when combined with the NPM1mt or the FLT3ITD genotypes, will serve as a poor prognostic marker in reducing DFS and OS in the favorable risk (NPM1mt/no FLT3ITD) patient group or worsening the patient outcomes in the unfavorable risk (FLT3ITD) group.